Nephrology

With the priority review acceptance of the Biologics License Application, the FDA has assigned a PDUFA target action date of November 28, 2025.

Stay updated with the latest healthcare breakthroughs, including weight loss treatments, pediatric therapies, and FDA approvals shaping the future of medicine.

Pregnancies occurring during or after initial C3G presentation were at a greater risk of preeclampsia, prematurity, and renal function decline.

With the sNDA acceptance, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026.

Recent research uncovers how lifestyle and environmental factors influence the incidence of IgAN and membranous nephropathy.

Symptoms of immunoglobulin A nephropathy were reduced substantially during the 1-month follow-up period.

The month in review spotlights renal FDA news and novel research about CKD and social determinants of health in kidney care.

From 1990-2021, global CKD-related deaths and DALYs attributable to physical inactivity increased, especially in low-SDI regions and among females.

Prophylactic treatment with IV magnesium led to a lower risk of cisplatin-associated AKI in patients with cancer undergoing cisplatin chemotherapy.

Several mobile apps effectively improved medication adherence in patients with CKD, posing important implications for their impact on clinical outcomes.

Kraus explains current unmet needs in IgA nephropathy and what sibeprenlimab may offer based on the phase 3 VISIONARY study.

Black patients disproportionately started dialysis at low-quality facilities and were less likely to have nephrologists with high-quality primary facilities.

An audio recap of the top 5 stories in healthcare news from the week of 03/31-04/06.

Most patients preferred OLC over their previous phosphate binder, and pill number and size were identified as barriers to phosphate binder adherence.

Electronic health interventions improved medication adherence in kidney transplant recipients, with potential implications for improving patient outcomes.

Study findings suggest significant socioeconomic disparities in preemptive kidney transplantation rates in children and the need for targeted interventions.

Our Q1 recap for nephrology spotlights regulatory updates, new clinical trial data, and advancements in xenotransplant.

Data from nearly half a dozen trials suggests steroidal MRAs may provide little benefit in kidney transplant patients.

Using CURE-CKD Registry data, the analysis showed relatively rapid-onset CKD was common in people with prediabetes, especially with hypertension or ASCVD.

The approval indicates Novartis's atrasentan (Vanrafia) for proteinuria reduction in primary IgA nephropathy.

The March 2025 month in review spotlights a new episode of Crisis Point about CKD for National Kidney Month and renal FDA news.

Study findings suggest COVID-19 is linked to a greater risk of long-term kidney dysfunction and new-onset advanced CKD than influenza.

The first quarter of 2025 saw approvals in diabetes, depression, kidney disease, and pain, among others. Read more about high-impact approvals of Q1 now.

The FDA accepted an sNDA for pegcetacoplan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

The Biologics License Application submission for sibeprenlimab is supported by results from the phase 2 ENVISION and phase 3 VISIONARY clinical trials.